Ex vivo T cell-depleted versus unmodified allografts in patients with acute myeloid leukemia in first complete remission.
about
Use of lectins in immunohematologyEffects of T-Cell Depletion on Allogeneic Hematopoietic Stem Cell Transplantation Outcomes in AML PatientsThe role of pattern-recognition receptors in graft-versus-host disease and graft-versus-leukemia after allogeneic stem cell transplantationAlternative Donor Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid LeukemiaLong term renal survival in patients undergoing T-Cell depleted versus conventional hematopoietic stem cell transplants.Single-agent GVHD prophylaxis with posttransplantation cyclophosphamide after myeloablative, HLA-matched BMT for AML, ALL, and MDS.Composite end point of graft-versus-host disease-free, relapse-free survival after allogeneic hematopoietic cell transplantation.Comparison of outcomes at two institutions of patients with ALL receiving ex vivo T-cell-depleted or unmodified allografts.Adenovirus Viremia in Adult CD34(+) Selected Hematopoietic Cell Transplant Recipients: Low Incidence and High Clinical Impact.High Disease-Free Survival with Enhanced Protection against Relapse after Double-Unit Cord Blood Transplantation When Compared with T Cell-Depleted Unrelated Donor Transplantation in Patients with Acute Leukemia and Chronic Myelogenous Leukemia.Dynamical System Modeling to Simulate Donor T Cell Response to Whole Exome Sequencing-Derived Recipient Peptides Demonstrates Different Alloreactivity Potential in HLA-Matched and -Mismatched Donor-Recipient Pairs.Histopathologic Features of Cutaneous Acute Graft-Versus-Host Disease in T-Cell-Depleted Peripheral Blood Stem Cell Transplant Recipients.CD34-Selected Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Relapsed, High-Risk Multiple Myeloma.Concise review: the bone marrow niche as a target of graft versus host disease.Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: are we closer to knowing who needs it?T-cell depleted allogeneic hematopoietic cell transplants as a platform for adoptive therapy with leukemia selective or virus-specific T-cells.Immunotherapy in acute myeloid leukemia.Ex vivo T-cell depletion in allogeneic hematopoietic stem cell transplant: past, present and future.Early recovery of T-cell function predicts improved survival after T-cell depleted allogeneic transplant.Allogeneic hematopoietic stem cell transplantation for nonmalignant hematologic disorders using chemotherapy-only cytoreductive regimens and T-cell-depleted grafts from human leukocyte antigen-matched or -mismatched donorsA Chemotherapy-Only Regimen of Busulfan, Melphalan, and Fludarabine, and Rabbit Antithymocyte Globulin Followed by Allogeneic T-Cell Depleted Hematopoietic Stem Cell Transplantations for the Treatment of Myeloid Malignancies.Co-Infections by Double-Stranded DNA Viruses after Ex Vivo T Cell-Depleted, CD34+ Selected Hematopoietic Cell Transplantation.Ex Vivo CD34+-Selected T Cell-Depleted Peripheral Blood Stem Cell Grafts for Allogeneic Hematopoietic Stem Cell Transplantation in Acute Leukemia and Myelodysplastic Syndrome Is Associated with Low Incidence of Acute and Chronic Graft-versus-Host DiHematopoietic Cell Transplantation Comorbidity Index Predicts Outcomes in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndromes Receiving CD34+ Selected Grafts for Allogeneic Hematopoietic Cell Transplantation.Second Allogeneic Stem Cell Transplantation for Acute Leukemia Using a Chemotherapy-Only Cytoreduction with Clofarabine, Melphalan, and Thiotepa.In-vivo or ex-vivo T cell depletion or both to prevent graft-versus-host disease after hematopoietic stem cell transplantation.Long-term prognosis for 1-year relapse-free survivors of CD34+ cell-selected allogeneic hematopoietic stem cell transplantation: a landmark analysis.FLT3-ITD mutations do not impact the outcome of patients allografted with partial T-cell depleted grafts for AML with normal cytogenetics in first complete remission.Tissue Damage Caused by Myeloablative, but Not Non-Myeloablative, Conditioning before Allogeneic Stem Cell Transplantation Results in Dermal Macrophage Recruitment without Active T-Cell Interaction.Ex vivo and in vivo T cell-depleted allogeneic stem cell transplantation in patients with acute myeloid leukemia in first complete remission resulted in similar overall survival: on behalf of the ALWP of the EBMT and the MSKCC
P2860
Q26751752-43482C75-27C1-4131-AD39-A60A5B6B0AEAQ26799602-23E8C971-5767-483E-B6F3-3253879CBCCCQ26824436-9AB6BFE5-BD78-4DE0-BD46-93FEDB453503Q28080943-32612E3F-C9B0-4FA7-947C-81F93D244278Q33633514-D11FDC9C-27AB-4765-8B3D-3E383E6FA7C2Q34684038-33966399-9E98-413B-950D-F60D0AB6D303Q35103562-C0D5CCD5-4046-4700-8E5D-FEDFD29461ACQ35243578-DD6EA636-E7EE-47DF-908D-6D885EAC88EFQ36445556-1835B815-E534-426C-AEE5-1ED5A7C5EFD8Q36622322-B30AA170-39A2-4D0E-8F5D-EC6E81DEEC94Q37114320-A6778C2F-2BAF-4C54-8676-70FEEEE6F690Q37139105-11CD7990-E90B-48D3-90B2-C82A1B3EDBC6Q37155605-C4265D1B-5C62-4144-AB6F-295EEAD9D392Q38192559-DD556980-9C86-46EE-A486-A68BE8EA4472Q38199056-F998F5F3-EBCA-45DF-AE03-506EE6238C97Q38514497-8E47FECC-E518-4080-B797-1D0218725F80Q38533606-BD39EC00-483E-402C-A1AA-0F72AA2EA8D1Q38742867-1021C869-8C59-4D87-9415-B3845DA64EABQ39028818-3FC45290-2CC7-42BE-91F5-F82E78E91ECFQ39313203-9AAAF49E-A4EB-4249-B85B-CFEE22DDBB27Q40121414-39421D8C-5DB0-4CB3-A13F-BD3451656D85Q40138389-1D1A130D-9C88-4294-AD9D-A83E1711ABD0Q40407930-D557A897-B7FA-4207-A6E6-F37B1DF31781Q40508324-7161CC6A-5738-46C3-9E6C-C7643527F45FQ40752008-9B870F33-7F2B-4025-B5A8-08F3C0412648Q48680865-44C691B4-F54C-477A-8B2B-CE92A7DE2A98Q49391428-0A17FD0C-DE44-4278-A29B-2B1BA148B472Q52902952-1EF8B248-C288-4878-9C07-2ED67D4221BEQ55175732-B5B7C2BA-F1CD-4AC4-BC4D-23404D27A52AQ57808500-5B5D5D7E-D8F9-4494-B265-970D114DC03F
P2860
Ex vivo T cell-depleted versus unmodified allografts in patients with acute myeloid leukemia in first complete remission.
description
2013 nî lūn-bûn
@nan
2013 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի մարտին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Ex vivo T cell-depleted versus ...... a in first complete remission.
@ast
Ex vivo T cell-depleted versus ...... a in first complete remission.
@en
type
label
Ex vivo T cell-depleted versus ...... a in first complete remission.
@ast
Ex vivo T cell-depleted versus ...... a in first complete remission.
@en
prefLabel
Ex vivo T cell-depleted versus ...... a in first complete remission.
@ast
Ex vivo T cell-depleted versus ...... a in first complete remission.
@en
P2093
P2860
P50
P1476
Ex vivo T cell-depleted versus ...... a in first complete remission.
@en
P2093
Alexander Chiattone
Ann A Jakubowski
Borje S Andersson
Esperanza B Papadopoulos
Farid Boulad
Gabriela Rondon
Hugo R Castro-Malaspina
Julianne Chen
Marcos de Lima
Richard E Champlin
P2860
P304
P356
10.1016/J.BBMT.2013.02.018
P577
2013-03-01T00:00:00Z